Mulmit

QuidelOrtho CorpQuidelOrtho Corp

QDEL Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-282,730,200,000-919,200,000-1,131,800,000-16.69
2024-12-292,782,900,000-1,960,900,000-2,052,000,000-30.54
2023-12-312,997,800,000139,100,000-10,100,000-0.15
2023-01-013,266,000,000843,700,000548,700,0009.56
2022-01-021,698,600,000906,000,000704,200,00016.43

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-09-15Bowman Ronald LeeChief Human Resources Officer2,566
2026-09-15Bowman Ronald LeeChief Human Resources Officer921
2026-09-15Bowman Ronald LeeChief Human Resources Officer2,566
2026-08-15Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting446
2026-08-15Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting162
2026-08-15Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting446
2026-07-15Young Micah WChief Financial Officer356,555
2026-07-01Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting5,797
2026-07-01Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting2,096
2026-07-01Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting5,797
2026-06-25Wilkins Joseph D Jr.15,532
2026-06-25Chiminski John R15,532

8-K events

FiledItems
2026-08-06Results of operations · Financial statements and exhibits
2026-06-23Officer or director change · Regulation FD disclosure · Financial statements and exhibits
2026-06-16Submission of matters to a vote
2026-05-05Results of operations · Financial statements and exhibits
2026-04-15Results of operations · Financial statements and exhibits
2026-03-24Officer or director change · Regulation FD disclosure · Financial statements and exhibits
2026-02-13Officer or director change
2026-02-11Results of operations · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

In Vitro & In Vivo Diagnostic Substances — 같은 업종, 그리고 규모가 비슷한 기업In Vitro & In Vivo Diagnostic Substances — and other companies of a similar size

SEC가 같은 업종(In Vitro & In Vivo Diagnostic Substances)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (In Vitro & In Vivo Diagnostic Substances) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.